Interpretation of Chinese Expert Consensus on the Diagnosis and Management Strategy of Patients with Statin Intolerance: A guiding file for lipid management in Chinese population
-
摘要: 业已证实，低密度脂蛋白胆固醇(LDL-C)水平升高是动脉粥样硬化性心血管疾病(ASCVD)发生的致病性危险因素，他汀类药物的临床应用开启了ASCVD病因学治疗的新时代。同时，他汀类药物也是国内外众多指南一致推荐的血脂管理及防治ASCVD的基石性药物。然而，他汀类药物不耐受现象(简称他汀不耐受)临床上并非少见，真实世界临床实践中的诊断与处理也存在困惑与误区。据此，国家心血管病专家委员会心血管代谢医学专业委员会组织国内相关专家，起草发布了《他汀不耐受的临床诊断与处理中国专家共识》，旨在提高他汀不耐受的基本认知和ASCVD的防治水平。本文就此共识的核心要点作一解读，以飨读者。
-
关键词:
- 他汀不耐受 /
- 动脉粥样硬化性心血管疾病 /
- 高脂血症 /
- 专家共识
Abstract: It is well-known that elevated low-density lipoprotein cholesterol(LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease(ASCVD), Statins are cornerstone drugs for the cause-based treatment of ASCVD, which has created a new era for ASCVD therapy. However, statin intolerance is not clinically uncommon, which there are several issue with confusion and misunderstandings. Hence, a file named Chinese Expert Consensus on the Diagnosis and Management Strategy of Patients With Statin Intolerance, like a navigator, has recently been published written by a team of experts from the Cardiovascular Metabolic Medicine Professional Committee, Expert Committee of the National Center for Cardiovascular Diseases aiming to enhance the standardized clinical application of statins and improve the prevention and clinical outcome. In this article, author briefly summarized the key points of above consensus in order to helping to comprehending the content of the consensus suggestions. -
-
[1] Li JJ, Liu HH, Li S. Landscape of cardiometabolic risk factors in Chinese population: An narrative review[J]. Cardiovasc Diabetol, 2022, 21(1): 113. doi: 10.1186/s12933-022-01551-3
[2] 李建军, 杨进刚. "融合"学说: 胆固醇、炎症与动脉粥样硬化的新视野[J]. 临床心血管病杂志, 2022, 38(4): 265-266. doi: 10.13201/j.issn.1001-1439.2022.04.002
[3] Yang C, Wu YJ, Qian J, et al. Landscape of statin as a cornerstone in atherosclerotic cardiovascular disease[J]. Rev Cardiovasc Med, 2023, 24(12): 373. doi: 10.31083/j.rcm2412373
[4] Li JJ, Zhao SP, Zhao D, et al. 2023 Chinese guidelines for lipid management[J]. Front Pharmacol, 2023, 14: 1190934. doi: 10.3389/fphar.2023.1190934
[5] Kim BK, Hong SJ, Lee YZ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease(RACING): a randomised, open-label, non-inferiority trial[J]. Lancet, 2022, 400(10349): 380-390. doi: 10.1016/S0140-6736(22)00916-3
[6] 国家心血管病专家委员会心血管代谢医学专业委员会. 他汀不耐受的临床诊断与处理中国专家共识[J]. 中国循环杂志, 2024, 39(2): 105-115.
[7] Li JJ, Duo KF, Zhou ZG, et al. Chinese expert consensus on the clinical diagnosis and management of statin intolerance[J]. Clin Pharmacol Ther, 2024, 115(5): 954-964. doi: 10.1002/cpt.3213
[8] Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient[J]. J Clin Lipidol, 2022, 16(4): 361-375. doi: 10.1016/j.jacl.2022.05.068
[9] Chien SC, Chen PS, Huang YH, et al. 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance[J]. J Formos Med Assoc, 2019, 118(10): 1385-1392. doi: 10.1016/j.jfma.2018.11.017
[10] Kajinami K, Tsukamoto K, Koba S, et al. Statin intolerance clinical guide 2018[J]. J Atheroscler Thromb, 2020, 27(4): 375-396. doi: 10.5551/jat.50948
[11] Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group update(2016)[J]. Can J Cardiol, 2016, 32(7 Suppl): S35-65.
[12] Li JJ, Liu HH, Wu NQ, et al. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects[J]. Expert Opin Drug Metab Toxicol, 2020, 16(9): 837-851. doi: 10.1080/17425255.2020.1802426
[13] Liu J, Luo SH, Qing P, et al. Comparative study of high-dose Xuezhikang and low-dose Xuezhikang plus Ezetimibe on pro-and anti-inflammatory markers[J]. Clin Lipidol, 2013, 8(1): 151-157. doi: 10.2217/clp.12.90
-
计量
- 文章访问数: 324
- 施引文献: 0
下载: